Innovation: “The Adherence Profile”
A manufacturer is often credited for creating the ubiquitously adopted measurement of Annualized Bleed Rate (ABR).
To best communicate their product’s competitive advantage, this manufacturer developed an aggregate data set (ABR) that measured bleeding in an easily digestible and comparable way, then used it to market their product over competitors’ products. Baxter was able to create a data set that made the health & safety argument for their product irrefutable, and married that with studies that demonstrated tremendous cost savings through reduced emergency department visits, hospitalizations, surgeries, etc., when patients had safe, reliable product like theirs.
So, even if payers initially hated the idea of putting -- in the case of Medicaid -- 5,858 hemophiliacs on prophylactic factor treatment, ABR shifted the debate on prophylaxis from “prophy or no prophy?” to “how much prophy should be prescribed?” In spite of the huge cost implications for payers, ABR’s strength helped shift the conversation from “is this regimen necessary?” to “how do we optimize management of this?”
The concept of an Annualized Bleed Rate reframed the dialog around treatment so effectively that today it’s hard to imagine the hemophilia world without it.
In an era where factor is once again in need of making a winning argument, and as numerous factor producers emphasize things such subclinical and microbleeds and the value of understanding PK, it is a perfect time for The Logging Tourniquet to revolutionize compliance, logging, and actual factor usage through the introduction of its technology in conjunction with the introduction of ”The Adherence Profile (AP).”
Instead of continuing to speak about compliance rates in the abstract, we propose building out Adherence Profiles using the relevant data sets to create an easily digestible and comparable figure that clearly demonstrates the deep relationship between improved adherence, and improved clinical outcomes and cost-savings goals over time.
For instance, Medicaid alone spends almost $800,000,000 annually supplying people with hemophilia (PWH) in the USA with clotting factor concentrate (CFC). If we could demonstrate through a well-designed study that improvement to one’s Adherence Profile by, say, “1 point” was the equivalent to saving a modest 1% on treatment and care costs - we could redefine how payers and patients were incentivized to treat and manage care. Saving 1% on PWH using CFC would mean Medicaid would save $8,000,000 on hemophilia CFC alone, not to mention the increased system savings from patients who are more adherent: reduced ER visits, fewer missed workdays, better quality of life.
Though our background is in bleeding disorders, any intravenous drugs administered regularly could be tracked and managed similarly, with the expectation of improved data accuracy, health outcomes, and relative cost-savings.
The Logging Tourniquet has the potential to revolutionize:
Adherence Profiles
Factor Lot Tracking & Safety
Data Accuracy
Clinical Outcomes
Cost-Savings
Patient Responsibility